Nxera Pharma , Ltd. Common Stock

As of the most recent data (June 2026), SOLTF shows a common stock of $48B. That compares with $47B in the prior-year period — up 1.5% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, SOLTF's common stock is now $48B (was $47B) — a 1.5% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Nxera Pharma , Ltd. is outperforming or lagging.

Tracking SOLTF's common stock over time shows whether Nxera Pharma , Ltd. is scaling, shrinking, or reshaping that part of the business. The current reading is $48B That compares with $47B in the prior-year period — up 1.5% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this common stock page, Stockcircle has Nxera Pharma , Ltd.'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect common stock (currently $48B) with ownership activity and broader fundamentals.

Nxera Pharma , Ltd.'s common stock is $48B; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.